• Call us
  • +919824102451 / (02646) 221825 / 221678
  • Email
  • info@elampharma.com / elampharma92@gmail.com



Today, EPPL is one of the most well-known manufacturers of Mebendazole. Other products of EPPL include Albendazole, Diclofenac Sodium, as well as a number of other intermediates used in the manufacture of the said products.

Product Name End Use
Albendazole Anthelmintic
Mebendazole Anthelmintic
Diclofenac Sodium Anti-Inflammatory

The company is committed to maintain international quality standards for its entire range of products through constant process and technology updates.
EPPL was a company with a mere 4 reactors when established, has now grown to a considerable size of 38 reactors spread across approximately 7000 square meters of land.

Land Approximately 7000 square meters
Building 4 blocks with Ground + 3 floors construction
Stainless Steel Reactors 26
Glass Line Reactors 07

We have 4 different blocks within the premises with reactor capacities ranging from 500L to 10kL, with a combined reactor volume of 1.26 mega-liters. We also have a full-fledged pilot plant with glass line reactors, stainless steel reactors and glass assemblies, where we can carry out development of new products and chemical reaction studies before taking the products into commercial production.
A macro view of the infrastructure can be gauged by the production capacity of the plant as given below:

Product Name Production Capacity (MT/month)
Albendazole 10
Mebendazole (off white) 15
Diclofenac Sodium 25

The company has all the valid permits and licenses required for the smooth functioning of the company, such as:
     • Factory Act License
     • Gujarat Pollution Control Board Consent
     • Explosive License
     • Prohibition License
     • Revised Schedule ‘M’- FDA
     • API Manufacturing License

Company Past
Since its inception the company has grown from pillar to post and has established quite a name for itself in the local as well global market. EPPL has exported to a number of countries such as Bangladesh, Brazil, Cyprus, Egypt, France, Germany, Italy, Kenya Mexico, Pakistan, South Korea, Sri Lanka, Vietnam, Singapore and UAE.
In the local market, we cater to well renowned companies which include a number of MNC’s.
EPPL also offers the Open part of DMF for Mebendazole and Albendazole.
Current Scenario
Presently, EPPL manufactures Diclofenac Sodium and its intermediates for the local market. We also have a number of new API’s and intermediates which have crossed the development stage and are ready to be commercialized, a few of which are listed below :

Sr.No. Chemical / Intermediate Name Common Name CAS No. End Use in API
1 3,4-Dihydro-7-(4-bromobutoxy)-2(1H)-quinolinone BBQ 129722-34-5 Aripiprazole
2 7-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one Aripiprazole Base 129722-12-9 Aripiprazole
3 5-Amino Salicylic Acid 5-ASA 89-57-6 Mesalamine or Mesalazine
4 5-[2-Ethoxy-5-(4-methylpiperazin-1-yl-sulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazol[4,3d]pyrimidin-7-one Sildenafil Base 139755-83-2 Sildenafil Citrate
5 Benzoyl Peroxide - 94-36-0 -
6 Tramadol Base and Intermediates - 1109217-84-6 (Base)22204-88-2(HCl) Opiod Analgesic
7 2 Chloromethyl 3,5-dimethyl 4-methoxy pyridine hydrochloride - 86604-75-3 Omeprazole
8 Chlorhexidine base - 55-56-1 Chlorhexidine Glucoate
9 N-Chloroacetyl-N-phenyl-2,6-dichloroaniline CPDCA 15308-01-7 Diclofenac Salts
10 1-(2, 6- Dichlorophenol)-2-Indolinone INDOLENONE 15307-86-5 Diclofenac Salts
11 2,6-Dichlorodiphenylamine DCDPA 15307-93-4 Diclofenac Salts
12 Diclofenac Sodium - 15307-79-6 API

Future Scope
With WHO declaring Albendazole as an essential drug for the African nations, EPPL is looking to tap the export market for the African nations. The launching of the above mentioned products in the market will boost the credibility as well as financials of the company to a considerable extent. The local market for Diclofenac Sodium is ripe as ever and for EPPL, exporting the API to non-regulated markets is next on the cards. Also, the planning for future growth includes getting a WHO certificate for the manufacturing facility and expansion in manufacturing capacities of the existing APIs.

© 2017 Elam Pharma Pvt Ltd | Design by JWS Technology
Choose Theme Options